X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (62) 62
female (61) 61
breast cancer (54) 54
oncology (52) 52
breast neoplasms - drug therapy (39) 39
middle aged (39) 39
chemotherapy (36) 36
adult (34) 34
index medicus (31) 31
aged (30) 30
breast neoplasms - pathology (29) 29
chemotherapy, adjuvant (29) 29
treatment outcome (25) 25
cancer (22) 22
breast neoplasms - mortality (21) 21
tamoxifen (18) 18
disease-free survival (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
therapy (15) 15
antineoplastic agents, hormonal - therapeutic use (14) 14
breast neoplasms - therapy (14) 14
clinical trials (14) 14
medicine & public health (13) 13
neoplasm staging (13) 13
prognosis (13) 13
tamoxifen - therapeutic use (13) 13
breast neoplasms - surgery (12) 12
follow-up studies (12) 12
lymphatic metastasis (12) 12
analysis (11) 11
care and treatment (11) 11
drug administration schedule (11) 11
research (11) 11
risk factors (11) 11
surgery (11) 11
adjuvant treatment (10) 10
cancer therapies (10) 10
drug therapy (10) 10
hematology, oncology and palliative medicine (10) 10
postmenopausal women (10) 10
survival analysis (10) 10
breast neoplasms - metabolism (9) 9
medicine, general & internal (9) 9
quality of life (9) 9
randomized controlled trials as topic (9) 9
trastuzumab (9) 9
antineoplastic agents (8) 8
antineoplastic agents - therapeutic use (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
cyclophosphamide (8) 8
cyclophosphamide - administration & dosage (8) 8
endocrine therapy (8) 8
medical research (8) 8
radiotherapy (8) 8
aged, 80 and over (7) 7
aromatase inhibitors (7) 7
breast neoplasms - diagnosis (7) 7
fluorouracil - administration & dosage (7) 7
health aspects (7) 7
postmenopause (7) 7
receptors, estrogen - metabolism (7) 7
retrospective studies (7) 7
survival (7) 7
antineoplastic agents - adverse effects (6) 6
antineoplastic agents, hormonal - adverse effects (6) 6
breast neoplasms - chemistry (6) 6
breast neoplasms - genetics (6) 6
combined modality therapy (6) 6
expression (6) 6
genetic aspects (6) 6
mastectomy (6) 6
methotrexate - administration & dosage (6) 6
receptor (6) 6
receptor, erbb-2 - metabolism (6) 6
tamoxifen - administration & dosage (6) 6
tamoxifen - adverse effects (6) 6
time factors (6) 6
trial (6) 6
tumors (6) 6
women (6) 6
adjuvant chemotherapy (5) 5
adjuvant therapy (5) 5
antimitotic agents (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
article (5) 5
biomarkers, tumor - analysis (5) 5
breast neoplasms (5) 5
cancer patients (5) 5
clinical trials as topic (5) 5
docetaxel (5) 5
dose-response relationship, drug (5) 5
estrogen (5) 5
mortality (5) 5
nitriles - administration & dosage (5) 5
pathology (5) 5
patients (5) 5
phase-ii (5) 5
pregnancy (5) 5
proportional hazards models (5) 5
quality-of-life (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 4, pp. 297 - 305
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1101 - 1108
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 848 - 858
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 96, Issue 2, pp. 273 - 279
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9897, pp. 1021 - 1028
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 3, pp. 236 - 244
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9555, pp. 29 - 36
Journal Article